FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2009096514> ?p ?o ?g. }

• W2009096514 endingPage "557" @default.
• W2009096514 startingPage "549" @default.
• W2009096514 abstract "BackgroundConsensus reports over the past 10 years from the United States, Europe, United Kingdom, and Canada have not provided consistent guidelines for antithrombotic therapy of aortic valve bioprostheses for the three-month period after surgery. This study was conducted to determine if antithrombotic therapy was protective against TE with aortic bioprostheses 30 days or less after aortic valve replacement (AVR).MethodsFrom 1994 to 2000, 1,372 patients implanted with three currently marketed aortic bioprostheses, Medtronic Mosaic (Medtronic, Inc, Minneapolis, MN) (415 patients), Carpentier-Edwards SAV (462), and Carpentier-Edwards PERIMOUNT (495) (Edwards Lifesciences, Irvine, CA), with a mean age of greater than 70 years were evaluated. Patient populations were comparable, inclusive of concomitant coronary artery bypass grafting (CABG) for the overall populations and for patients greater than 70 years.ResultsThere were 37 thromboembolic (TE) events: major TE, 14; reversible ischemic neurologic deficit (RIND), 12; and minor TE, 11. There were 4 TE deaths. Multivariate (stepwise logistic regression) analysis revealed no predictive risk factors for overall TE. For the combination of major TE plus RIND there were two predictive risk factors with analysis of 12 risk variables: preoperative cerebrovascular accident (odds ratio [OR] 4.45, 95% confidence interval [CI] 1.17 to 16.87, p = 0.028); and concomitant CABG (OR 3.19, 95% CI 1.16 to 8.76, p = 0.025). Neither anticoagulant nor antiplatelet therapies gave significant protection.ConclusionsThere does not appear to be an indication for routine antithrombotic management. The study supports the potential use of antithrombotic therapy for comorbidities of preoperative cerebrovascular accident and concomitant CABG but not atrial fibrillation, left ventricular dysfunction, or elderly age greater than 70 years. Vascular burden and advanced age are likely contributing factors to these independent predictors. There may still be a need for, or at least consideration of, a randomized trial for AVR with bioprostheses. Consensus reports over the past 10 years from the United States, Europe, United Kingdom, and Canada have not provided consistent guidelines for antithrombotic therapy of aortic valve bioprostheses for the three-month period after surgery. This study was conducted to determine if antithrombotic therapy was protective against TE with aortic bioprostheses 30 days or less after aortic valve replacement (AVR). From 1994 to 2000, 1,372 patients implanted with three currently marketed aortic bioprostheses, Medtronic Mosaic (Medtronic, Inc, Minneapolis, MN) (415 patients), Carpentier-Edwards SAV (462), and Carpentier-Edwards PERIMOUNT (495) (Edwards Lifesciences, Irvine, CA), with a mean age of greater than 70 years were evaluated. Patient populations were comparable, inclusive of concomitant coronary artery bypass grafting (CABG) for the overall populations and for patients greater than 70 years. There were 37 thromboembolic (TE) events: major TE, 14; reversible ischemic neurologic deficit (RIND), 12; and minor TE, 11. There were 4 TE deaths. Multivariate (stepwise logistic regression) analysis revealed no predictive risk factors for overall TE. For the combination of major TE plus RIND there were two predictive risk factors with analysis of 12 risk variables: preoperative cerebrovascular accident (odds ratio [OR] 4.45, 95% confidence interval [CI] 1.17 to 16.87, p = 0.028); and concomitant CABG (OR 3.19, 95% CI 1.16 to 8.76, p = 0.025). Neither anticoagulant nor antiplatelet therapies gave significant protection. There does not appear to be an indication for routine antithrombotic management. The study supports the potential use of antithrombotic therapy for comorbidities of preoperative cerebrovascular accident and concomitant CABG but not atrial fibrillation, left ventricular dysfunction, or elderly age greater than 70 years. Vascular burden and advanced age are likely contributing factors to these independent predictors. There may still be a need for, or at least consideration of, a randomized trial for AVR with bioprostheses." @default.
• W2009096514 created "2016-06-24" @default.
• W2009096514 creator A5005007989 @default.
• W2009096514 creator A5032700450 @default.
• W2009096514 creator A5032750069 @default.
• W2009096514 creator A5032785279 @default.
• W2009096514 creator A5059044669 @default.
• W2009096514 creator A5061757764 @default.
• W2009096514 creator A5064040012 @default.
• W2009096514 creator A5065185437 @default.
• W2009096514 creator A5078871269 @default.
• W2009096514 creator A5082542186 @default.
• W2009096514 date "2007-02-01" @default.
• W2009096514 modified "2023-10-13" @default.
• W2009096514 title "Early Antithrombotic Therapy for Aortic Valve Bioprostheses: Is There an Indication for Routine Use?" @default.
• W2009096514 cites W1591699919 @default.
• W2009096514 cites W1969563698 @default.
• W2009096514 cites W1976485708 @default.
• W2009096514 cites W1978170036 @default.
• W2009096514 cites W1981746689 @default.
• W2009096514 cites W1990852664 @default.
• W2009096514 cites W2008635765 @default.
• W2009096514 cites W2044551635 @default.
• W2009096514 cites W2104286300 @default.
• W2009096514 cites W2112453876 @default.
• W2009096514 cites W2114110668 @default.
• W2009096514 cites W2143623373 @default.
• W2009096514 cites W2273075943 @default.
• W2009096514 doi "https://doi.org/10.1016/j.athoracsur.2006.07.041" @default.
• W2009096514 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17257986" @default.
• W2009096514 hasPublicationYear "2007" @default.
• W2009096514 type Work @default.
• W2009096514 sameAs 2009096514 @default.
• W2009096514 citedByCount "23" @default.
• W2009096514 countsByYear W20090965142012 @default.
• W2009096514 countsByYear W20090965142013 @default.
• W2009096514 countsByYear W20090965142015 @default.
• W2009096514 countsByYear W20090965142016 @default.
• W2009096514 countsByYear W20090965142018 @default.
• W2009096514 countsByYear W20090965142019 @default.
• W2009096514 countsByYear W20090965142020 @default.
• W2009096514 countsByYear W20090965142021 @default.
• W2009096514 crossrefType "journal-article" @default.
• W2009096514 hasAuthorship W2009096514A5005007989 @default.
• W2009096514 hasAuthorship W2009096514A5032700450 @default.
• W2009096514 hasAuthorship W2009096514A5032750069 @default.
• W2009096514 hasAuthorship W2009096514A5032785279 @default.
• W2009096514 hasAuthorship W2009096514A5059044669 @default.
• W2009096514 hasAuthorship W2009096514A5061757764 @default.
• W2009096514 hasAuthorship W2009096514A5064040012 @default.
• W2009096514 hasAuthorship W2009096514A5065185437 @default.
• W2009096514 hasAuthorship W2009096514A5078871269 @default.
• W2009096514 hasAuthorship W2009096514A5082542186 @default.
• W2009096514 hasConcept C126322002 @default.
• W2009096514 hasConcept C141071460 @default.
• W2009096514 hasConcept C156957248 @default.
• W2009096514 hasConcept C164705383 @default.
• W2009096514 hasConcept C2776570981 @default.
• W2009096514 hasConcept C2776820930 @default.
• W2009096514 hasConcept C2777015399 @default.
• W2009096514 hasConcept C2779384505 @default.
• W2009096514 hasConcept C2780007028 @default.
• W2009096514 hasConcept C2780714102 @default.
• W2009096514 hasConcept C3017915907 @default.
• W2009096514 hasConcept C44249647 @default.
• W2009096514 hasConcept C71924100 @default.
• W2009096514 hasConceptScore W2009096514C126322002 @default.
• W2009096514 hasConceptScore W2009096514C141071460 @default.
• W2009096514 hasConceptScore W2009096514C156957248 @default.
• W2009096514 hasConceptScore W2009096514C164705383 @default.
• W2009096514 hasConceptScore W2009096514C2776570981 @default.
• W2009096514 hasConceptScore W2009096514C2776820930 @default.
• W2009096514 hasConceptScore W2009096514C2777015399 @default.
• W2009096514 hasConceptScore W2009096514C2779384505 @default.
• W2009096514 hasConceptScore W2009096514C2780007028 @default.
• W2009096514 hasConceptScore W2009096514C2780714102 @default.
• W2009096514 hasConceptScore W2009096514C3017915907 @default.
• W2009096514 hasConceptScore W2009096514C44249647 @default.
• W2009096514 hasConceptScore W2009096514C71924100 @default.
• W2009096514 hasIssue "2" @default.
• W2009096514 hasLocation W20090965141 @default.
• W2009096514 hasLocation W20090965142 @default.
• W2009096514 hasOpenAccess W2009096514 @default.
• W2009096514 hasPrimaryLocation W20090965141 @default.
• W2009096514 hasRelatedWork W148041586 @default.
• W2009096514 hasRelatedWork W2024496703 @default.
• W2009096514 hasRelatedWork W2030717199 @default.
• W2009096514 hasRelatedWork W2066751879 @default.
• W2009096514 hasRelatedWork W2072807414 @default.
• W2009096514 hasRelatedWork W2315671836 @default.
• W2009096514 hasRelatedWork W2350791141 @default.
• W2009096514 hasRelatedWork W2611557181 @default.
• W2009096514 hasRelatedWork W2943312057 @default.
• W2009096514 hasRelatedWork W3024094360 @default.
• W2009096514 hasVolume "83" @default.
• W2009096514 isParatext "false" @default.
• W2009096514 isRetracted "false" @default.
• W2009096514 magId "2009096514" @default.

• next